Start Receiving Updates
Fill out this form to receive updates about INBRIJA.
Fill out this form to receive updates about INBRIJA.
Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Please Note: By clicking on this link, you are about to leave Inbrija-HCP.com, a website owned and operated by Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. provides these links as a service to its website visitors and users; however, it does not endorse or take any responsibility for the information presented on any websites but its own.
No thanks, I'll stay Take me thereYou are sharing
:The information you provide will be used by Acorda Therapeutics, Inc. in accordance with our Privacy Policy and by parties acting on Acorda's behalf to send them information on INBRIJA. View our Privacy Policy.
Our Statement on COVID-19
March 26, 2020
Since the initial outbreak of COVID-19, Acorda has been closely monitoring our supply chain for potential impact to the supply of our medicines. Acorda manufactures INBRIJA® (levodopa inhalation powder) in the United States and sources active pharmaceutical ingredient (API) from Japan. INBRIJA continues to be available through a dedicated specialty pharmacy network. Acorda communicates with these dedicated pharmacies on a daily basis or as frequently as needed to ensure that all eligible patients continue to have uninterrupted access to their INBRIJA. All patient support services remain active and can be offered without interruption.
05/20 INB8868